# Xinrui Regeneration

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xinrui-regeneration

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Website: www.xremed.com
- Latest round: Angel (May 29, 2019)
- Investors on record: 1

## About

Based in Nanjing, China, and established in 2019, Xinrui Regeneration is a biology company that focuses on innovative drug development. The founding team and core members come from Peking University, Tsinghua University, Fudan University, and other universities, and have decades of research and industrial experience in the fields of stem cells and regenerative medicine, artificial intelligence, and drug discovery and development. The founder and Chief Scientist Officer, Yang Zhao is a researcher and doctoral director at the Institute of Molecular Medicine, Peking University Institute of Future Technology. In January 2022, Xinrui Regeneration raised CNY 10 million in pre-series A funding. In December 2022, Suzhou Huace Bio reached a partnership with the company.

The company is committed to developing innovative drugs for in situ tissue and organ regeneration, fibrosis reversal, and tumor cell reprogramming. It has built a small molecule drug discovery platform CReDIT (Cell Revitalizing Drug Innovation Technology) based on cell reprogramming technology, high-throughput genomics, and artificial intelligence. The technical services include the phenotype evaluation technology platform, disease cell model construction technology platform, and compound services. It also provides Swift CellSignature High-Throughput RNA extraction Kit, 96-well side magnetic rack, and other products.

The company generates revenue by developing innovative drugs.

## Funding rounds

- Angel, May 29, 2019 — Casstar Capital

## Investors

- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Angel